Azole compounds used as tuberculostatic and leishmanicide agents
AssigneeFundacao Oswaldo Cruz - FIOCRUZ
InventorsNubia Boechat, Marilia dos Santos Costa, Maria Cristina da Silva Lourenco, Ivan Neves, Jr., Marcelo da Silva Genestra, Vitor Francisco Ferreira
Life of this patent
Estimating the term…
Abstract
This invention refers to new 1,2,3-triazole and imidazole compounds included in the families of compounds represented by general formula VIII. This invention also refers to a pharmaceutical composition comprising at least one of the azole compounds represented by the general formula VIII, to the use of such compositions and to method of treatment or inhibition of tuberculosis and leishmaniasis.
Claims9
A method of treating or inhibiting tuberculosis or leishmaniasis, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition to treat or inhibit tuberculosis or leishmaniasis, wherein the pharmaceutical composition comprises an azole compound and a pharmaceutically acceptable carrier, and
- wherein the azole compound is a 1,2,3-triazole, or one of its salts, represented by the general formula VIII:
- where:
- X is “N” and the radicals of the triazole ring are represented by:
- R1═CF2R6;
- R6═R10=alkyl;
- and
- where radical Rn can be located in any one or in more than one of the carbon atoms of the aromatic ring, and is represented by a halogen,
- thereby treating or inhibiting tuberculosis or leishmaniasis.
A method of treating or inhibiting tuberculosis or leishmaniasis, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition to treat or inhibit tuberculosis or leishmaniasis, wherein the pharmaceutical composition comprises an azole compound selected from the group consisting of:
- 1-(3-chlorophenyl)-4-difluoromethyl-1H-1,2,3-triazole,
- 1-(3,5-dichlorophenyl)-4-difluoromethyl-1H-1,2,3-triazole, and
- one of their salts.
A method of treating or inhibiting tuberculosis or leishmaniasis, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition to treat or inhibit tuberculosis or leishmaniasis, wherein the pharmaceutical composition comprises an azole compound selected from the group consisting of:
- (AND)-4-chloride-N-((1-(4-chlorophenyl)-1H-1,2,3-triazole-4-il)methylene)benzenamine,
- (AND)-4-bromo-N-((1-(4-bromophenyl)-1H-1,2,3-triazole-4-il)methylene)benzenamine, and
- one of their salts.
Dependencies are inferred from the claim text.